Nordic ListingsIssuer Report
BioGaia AB: Quarterly Trading Report 2025 Q3
BioGaia AB: Quarterly Trading Report 2025 Q3https://view.news.eu.nasdaq.com/view?id=b13266d6a2ee0c03b87f3fe5ed7b49823&lang=en&src=omxlink
BioGaia AB: Quarterly Trading Report 2025 Q3
Earlier from BioGaia
- BIOG_B: Q2 saw 5% sales growth and direct channel expansion, but EBIT dropped 20% on higher OpEx
- BIOG_B: Flat sales, lower EBIT, strong Americas growth, and direct sales shifts set up H2 rebound
- BIOG_B: BioGaia achieved 10% sales growth and strong segment expansion, maintaining high margins
- BIOG_B: Sales fell 4% as EMEA lagged, but Asia Pacific and Americas posted strong growth
- BIOG_B: Q2 sales up 22%, EBIT margin 35%, and APAC growth led BioGaia's strong quarter
Later from BioGaia
- BIOG_B: Sales up 7%, EBIT margin 26%, direct markets and innovation drive future growth
- BioGaia's prelim Q4 sales rise 21%, margins expand
- BIOG_B: Q4 organic sales up 32%, EBIT margin 27%, and direct markets now 40% of sales
- BioGaia Extends Distribution Partnership With Ewopharma
- BioGaia Exercises Option To Acquire Remaining Shares In Nutraceutics
Follow BioGaia into a list and get an email when it puts out news.
Follow BioGaia